JP2022527557A5 - - Google Patents
Info
- Publication number
- JP2022527557A5 JP2022527557A5 JP2021559256A JP2021559256A JP2022527557A5 JP 2022527557 A5 JP2022527557 A5 JP 2022527557A5 JP 2021559256 A JP2021559256 A JP 2021559256A JP 2021559256 A JP2021559256 A JP 2021559256A JP 2022527557 A5 JP2022527557 A5 JP 2022527557A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- enpp1
- mutant polypeptide
- polypeptide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024167228A JP2024178422A (ja) | 2019-04-05 | 2024-09-26 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830230P | 2019-04-05 | 2019-04-05 | |
| US62/830,230 | 2019-04-05 | ||
| US202062983142P | 2020-02-28 | 2020-02-28 | |
| US62/983,142 | 2020-02-28 | ||
| US202062984650P | 2020-03-03 | 2020-03-03 | |
| US62/984,650 | 2020-03-03 | ||
| PCT/US2020/026643 WO2020206302A1 (en) | 2019-04-05 | 2020-04-03 | Enpp1 polypeptides and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024167228A Division JP2024178422A (ja) | 2019-04-05 | 2024-09-26 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527557A JP2022527557A (ja) | 2022-06-02 |
| JP2022527557A5 true JP2022527557A5 (https=) | 2023-04-10 |
Family
ID=72667412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559256A Pending JP2022527557A (ja) | 2019-04-05 | 2020-04-03 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
| JP2024167228A Pending JP2024178422A (ja) | 2019-04-05 | 2024-09-26 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024167228A Pending JP2024178422A (ja) | 2019-04-05 | 2024-09-26 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220195402A1 (https=) |
| EP (1) | EP3947660A4 (https=) |
| JP (2) | JP2022527557A (https=) |
| KR (1) | KR20210149146A (https=) |
| CN (1) | CN113993993A (https=) |
| AU (2) | AU2020256253B2 (https=) |
| BR (1) | BR112021020037A2 (https=) |
| CA (1) | CA3136118A1 (https=) |
| IL (1) | IL286946A (https=) |
| MX (1) | MX2021012197A (https=) |
| TW (1) | TW202043292A (https=) |
| WO (1) | WO2020206302A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021252549A1 (en) | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| CA3246877A1 (en) * | 2022-03-30 | 2023-10-05 | Yale University | METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995019570A1 (en) * | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| ES2708565T3 (es) * | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| EP4414028A3 (en) * | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
-
2020
- 2020-04-03 CA CA3136118A patent/CA3136118A1/en active Pending
- 2020-04-03 BR BR112021020037A patent/BR112021020037A2/pt unknown
- 2020-04-03 JP JP2021559256A patent/JP2022527557A/ja active Pending
- 2020-04-03 MX MX2021012197A patent/MX2021012197A/es unknown
- 2020-04-03 EP EP20783595.0A patent/EP3947660A4/en active Pending
- 2020-04-03 CN CN202080041580.2A patent/CN113993993A/zh active Pending
- 2020-04-03 AU AU2020256253A patent/AU2020256253B2/en active Active
- 2020-04-03 KR KR1020217036178A patent/KR20210149146A/ko active Pending
- 2020-04-03 US US17/601,387 patent/US20220195402A1/en not_active Abandoned
- 2020-04-03 WO PCT/US2020/026643 patent/WO2020206302A1/en not_active Ceased
- 2020-04-06 TW TW109111502A patent/TW202043292A/zh unknown
-
2021
- 2021-10-04 IL IL286946A patent/IL286946A/en unknown
-
2024
- 2024-08-26 US US18/815,173 patent/US20250230423A1/en active Pending
- 2024-09-26 JP JP2024167228A patent/JP2024178422A/ja active Pending
-
2026
- 2026-01-30 AU AU2026200700A patent/AU2026200700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU778939B2 (en) | Expression and export of anti-obesity proteins as Fc fusion proteins | |
| JP2021535153A5 (https=) | ||
| TWI593708B (zh) | 治療代謝病症之融合蛋白質 | |
| JP2020171316A (ja) | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 | |
| US7087411B2 (en) | Fusion protein capable of binding VEGF | |
| JP7348980B2 (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| JP4988599B2 (ja) | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 | |
| JP2017529059A5 (https=) | ||
| JP2001510682A (ja) | 免疫グロブリンヒンジ領域リンカーを有する融合タンパク質 | |
| CN103974716B (zh) | 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 | |
| CN103159860B (zh) | 重组组织型纤溶酶原激活剂及其制备方法与用途 | |
| JP2022527557A5 (https=) | ||
| CN112673026B (zh) | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 | |
| JP2018503355A (ja) | Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用 | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| JP2025525452A (ja) | 細胞へのオリゴヌクレオチドの送達のためのトランスフェリン受容体結合分子コンジュゲート | |
| JP2024503725A (ja) | 小分子調節遺伝子発現システム | |
| AU2026200700A1 (en) | ENPP1 polypeptides and methods of using same | |
| JP7457413B2 (ja) | 代謝障害に対する新規なｆｇｆ１９タンパク質類似物質及びその使用 | |
| JP2022525661A (ja) | 組換えｃｃｎドメインタンパク質および融合タンパク質 | |
| JP2023529892A5 (https=) | ||
| CA3202364A1 (en) | Dsg2 compositions and methods for the treatment of covid-19 | |
| JP2022043051A (ja) | Ｇｍ－ｃｓｆ変異体及び使用方法 | |
| RU2021132096A (ru) | Enpp1 полипептиды и способы их применения | |
| JPH025892A (ja) | 組換えヒトインターロイキン―１αポリペプチド |